Table 3 Acute adverse effects for patients treated with adjuvant EBRT with/or VBT
|  | Patients (N = 218) | |||
|---|---|---|---|---|
EBRT (n = 51) | VBT (n = 25) | EBRT + VBT (n = 142) | p-value | |
Adverse Events | No. (%) | No. (%) | No. (%) | Â |
bUpper GI | Â | Â | Â | 0.001 |
 0 | 36 (70.6) | 21 (84.0) a2.5 | 77 (54.2) a-3.0 |  |
 1–2 | 15 (29.4) | 3 (12.0) a-2.9 | 65 (45.8) a3.2 |  |
 3 | 0 (0.0) | 1 (4.0) a2.8 | 0 (0.0) |  |
bLower GI | Â | Â | Â | 0.000 |
 0 | 27 (52.9) | 22 (88.0) a4.7 | 48 (33.8) a-4.3 |  |
 1–2 | 23 (45.1) | 3 (12.0) a-4.5 | 93 (65.5) a4.4 |  |
 3 | 1 (2.0) | 0 (0.0) | 1 (0.7) |  |
Urinary Tract | Â | Â | Â | 0.864 |
 0 | 44 (86.3) | 23 (92.0) | 123 (86.6) |  |
 1–2 | 7 (13.7) | 2 (8.0) | 18 (12.7) |  |
 3 | 0 (0.0) | 0 (0.0) | 1 (0.7) |  |
Hematological | Â | Â | Â | 0.023 |
 0 | 23 (45.1) | 21 (84.0) a3.1 | 75 (52.8) |  |
 1–2 | 25 (49.0) | 4 (16.0) a-2.7 | 60 (42.3) |  |
 3–4 | 3 (5.9) | 0 (0.0) | 7 (4.9) |  |